The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1.4 ,ug/ml in mice, rats, dogs, and humans, respectively. UK-49,858 [2-(2,4,-difluorophenyl)-1,3-bis(lH-1,2,4-triazol-1-yl)propan-2-ol; fluconazole; Fig. 1 ] is a new systemically acting antifungal agent which has shown activity in several animal models of infection (14; P. F. Troke, R. J. Andrews, K. W. Brammer, M. S. Marriott, and K. Richardson, Antimicrob. Agents Chemother., submitted for publication). Typical oral 50% protective dose values against acute lethal systemic candidiasis in mice range between 0.1 and 0.3 mg/kg, demonstrating that the compound is between 20-and 100-fold more potent than ketoconazole in this model. Results of several studies with imidazole antifungal agents have shown that the pharmacokinetics of these compounds have a significant impact on their comparative efficacy in vivo. The pharmacokinetic profiles of such imidazole antifungal agents as miconazole (3, 12), econazole (13), and clotrimazole (7, 15) were characterized by poor oral bioavailability and low plasma concentrations due to significant first-pass metabolism and a large volume of distribution. The recent introduction of ketoconazole (1) has seen the advent of imidazole antifungal drugs with good systemic bioavailability and relatively high plasma concentrations. However, in common with previous imidazoles, ketoconazole is highly bound to plasma proteins (4, 11), is extensively metabolized (9), and exhibits dose-dependent kinetics in both animals (1) and humans (2, 5). This report describes the pharmacokinetic profile of the bistriazole UK-49,858, which is markedly different from that of ketoconazole and related imidazoles and assesses the potential contribution of this profile to the efficacy of the drug in vivo. 
The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1. 4 ,ug/ml in mice, rats, dogs, and humans, respectively. The volumes of distribution ranged between 1.1 liter/kg in mice and 0.7 liter/kg in humans, which are approximate to the values for total body water. Whole body autoradiography studies in mice following intravenous administration of [14C] UK-49,858 demonstrated that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Plasma protein binding was low (11 to 12%) in all species. Marked species differences were observed in elimination half-lives, with mean values of 4.8, 4.0, 14 , and 22 h in mice, rats, dogs, and humans, respectively. The major route of elimination of the drug was renal clearance, with about 70% of the dose being excreted unchanged in the urine in each species. Studies with
[14C]UK-49,858 on metabolism and excretion (intravenous and oral) in mice and dogs showed that about 90% of the dose was recovered as unchanged drug in urine and feces, confirming the metabolic stability of the drug. This pharmacokinetic profile is markedly different from that of imidazole antifungal drugs and undoubtedly contributes to the excellent efficacy of UK-49,858 in vivo.
UK-49,858 [2-(2,4,-difluorophenyl)-1,3-bis(lH-1,2,4-triazol-1-yl)propan-2-ol; fluconazole; Fig. 1 ] is a new systemically acting antifungal agent which has shown activity in several animal models of infection (14; P. F. Troke, R. J. Andrews, K. W. Brammer, M. S. Marriott, and K. Richardson, Antimicrob. Agents Chemother., submitted for publication). Typical oral 50% protective dose values against acute lethal systemic candidiasis in mice range between 0.1 and 0.3 mg/kg, demonstrating that the compound is between 20-and 100-fold more potent than ketoconazole in this model. Results of several studies with imidazole antifungal agents have shown that the pharmacokinetics of these compounds have a significant impact on their comparative efficacy in vivo. The pharmacokinetic profiles of such imidazole antifungal agents as miconazole (3, 12) , econazole (13) , and clotrimazole (7, 15) were characterized by poor oral bioavailability and low plasma concentrations due to significant first-pass metabolism and a large volume of distribution. The recent introduction of ketoconazole (1) has seen the advent of imidazole antifungal drugs with good systemic bioavailability and relatively high plasma concentrations. However, in common with previous imidazoles, ketoconazole is highly bound to plasma proteins (4, 11) , is extensively metabolized (9) , and exhibits dose-dependent kinetics in both animals (1) and humans (2, 5) . This report describes the pharmacokinetic profile of the bistriazole UK-49,858, which is markedly different from that of ketoconazole and related imidazoles and assesses the potential contribution of this profile to the efficacy of the drug in vivo. were given by esophageal tube and washed in with water (10 ml). Blood samples were drawn from the cephalic veins by venipuncture at intervals up to 72 h after the dose was administered. Oral and intravenous doses to the same animal were separated by 14 days.
MATERIALS AND METHODS
The pharmacokinetic profile in humans was determined in four male volunteers (age range, 18 to 45 years; weight range, 63 to 70 kg). Following an overnight fast each subject received a solution of UK-49,858 at a dose of 1 mg/kg followed by 150 ml water. A standard meal was provided 2 h after dosing. Blood samples were drawn from the antecubital veins at intervals up to 72 h after the dose was administered. Total voided urine was collected at daily intervals up to 72 h.
Blood from all studies was collected in lithium heparin tubes and centrifuged to separate plasma, which was stored at -200C.
Pharmacokinetic parameters. Pharmacokinetic parameters for the drug were estimated by fitting the plasma concentration data to one-compartment open models by least-squares regression analysis. Values for area under the plasma concentration-time profiles, oral bioavailability, total plasma clearance, renal clearance, volume of distribution, and halflife were calculated by conventional formulas described " Concentration data were obtained by using pooled plasma samples from five animals for each time point in mice and rats and from serial plasma samples in dogs (n = 2) and humans (n = 4). AUC0 ,, Area under the plasma concentration-time curve.
" Recoveries are following oral administration and were determined in separate experiments. Values represent data from pooled samples in mice (n = 3), and mean ± standard deviation for rats (n = 4), dogs (n = 3), and humans (ni = 4). Analysis of samples. Samples of plasma and urine from pharmacokinetic studies were assayed by a gas chromatographic method specific for the drug (M. H. Tarbit and P. R. Wood, manuscript in preparation). Briefly, samples (0.1 to 1 ml) were made basic with 1 M sodium hydroxide (1 ml) and extracted with ethyl acetate (3 ml). The organic phase was transferred to clean glass tubes and back extracted with 1 M HCI (2 ml). The organic phase was then discarded, and the aqueous phase was again made basic with 5 M NaOH (1 ml) follwed by extraction with ethyl acetate (3 ml Pharmacokinetic parameters of the drug in each species are shown in Table 3 . Values for volume of distribution, calculated from plasma clearance and half-life values following intravenous administrations, were 1.1 and 0.7 liter/kg in mice and dogs, respectively, and were similar to values calculated assuming complete bioavailability in oral studies in rats and humans. This volume of distribution is approximate to that for total body water and suggests that the drug Fig. 3 . The results show that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Only the organs responsible for elimination of the drug, the liver and kidneys, showed accumulation above that in blood. Autoradiographs at 24 h after the dose was administered showed that the drug and its metabolites were essentially eliminated within 24 h of dosing. Plasma protein binding was low in all species, with values (±standard deviation) being 12 ± 0.8, 12 ± 0.7, 11 ±1.1, and 11 ± 0.4% in mice, rats, dogs, and humans, respectively, and did not vary over the concentration range tested.
A marked species difference was evident in the elimination half-life of UK-49,858 (Table 3) , with half-life values ranging from about 4 h in rodents to 22 h in humans. Since the volume of distribution of the drug was similar in all species, the different half-life values reflect species differences in total plasma clearance. Analysis of urine for the percentage of dose excreted unchanged (Table 2) showed that the major route of elimination of drug in all species was by renal clearance.
Disposition. Detailed studies on the disposition of [14C] UK-49,858 were carried out in mice and dogs following oral and intravenous administrations. The percentages of dose excreted in urine and feces in each species are shown in Table 4 . The major route of excretion of drug-related material in mice and dogs was via the urine, accounting for about 80% of the dose in both species following intravenous administration. Radioactivity in the feces (Table 4) (Table 5) , with unchanged drug in urine representing 88.9 and 90.5% of urinary radioactivity (64 and 71% of the dose) following oral and intravenous admninistration, respectively. Chromatographic analysis of dog feces was not attempted as excretion of radioactivity was low.
Three minor radioactive metabolites were observed in the urine of both species ( (11) . Consequently, absolute oral bioavailability cannot be determined. However, in contrast to UK-49,858, the oral bioavailability of ketoconazole appears to be variable in laboratory species (9) and dose dependent in animals (1) and humans (2) .
Protein binding of UK-49,858 is low (11 to 12%); consequently, the major portion of the drug present in the body is unbound and is available for antifungal activity in tissues. This is in contrast to the imidazole antifungal agents, including ketoconazole, in which plasma protein binding is typically in excess of 98% (4) . This 40-to 50-fold difference in unbound fractions of UK-49,858 and ketoconazole in plasma is likely to be a significant contributory factor to the 20-to 100-fold potency advantage of UK-49,858 in vivo over ketoconazole (14; Troke et al., submitted). The significant penetration of UK-49,858 into the brain and cerebrospinal fluid of mice observed in the whole body autoradiography studies is also in contrast to the poor and variable levels in cerebrospinal fluid reported for miconazole (6, 8) and ketoconazole (4). These findings suggest that UK-49,858 may exhibit greater efficacy against fungal infections of the brain than current imidazole drugs.
A further possible contribution to the improved efficacy of UK-49,858, relative to that of ketoconazole, is the greater and more prolonged systemic exposure to the drug, reflecting a smaller volume of distribution and lower clearance.
Half-lives for UK-49,858 in plasma were longer in each species than those reported for ketoconazole, which has half-life values of 2.0, 1.1, 2.8, and about 3.0 h in mice (unpublished data), rats (9) , dogs (9) and humans (2), respectively. The difference in half-lives between the compounds in humans is most striking, and it is apparent that continuous exposure to significant concentrations of UK-49,858 can be achieved by administration once daily.
The clearest distinction between the bis-triazole UK-49,858 and current systemic imidazole antifungal agents is evident in the routes of elimination. Renal clearance is the major route of excretion of UK-49,858, with metabolism accounting for less than 10% of total drug excreted in mice and dogs. This pattern of excretion reflects the relative polarity and metabolic stability of the drug, unlike other imidazole antifungal drugs, including miconazole and ketoconazole, all of which are extensively metabolized in animals and humans (3, 4, 11, 13, 16) .
The results presented here demonstrate that UK-49,858 has novel pharmacokinetic properties, including good oral bioavailability and prolonged systemic exposure, low protein binding, even tissue distribution, and extensive renal clearance. This profile is undoubtedly a major contributory factor to the efficacy of the drug in animal models of fungal infections and may lead to enhanced efficacy in humans.
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